Chemotherapy for childhood acute lymphoblastic leukemia (ALL) is associated with alterations in brain activation during attention and executive-function tasks, researchers report.Reuters Health Information

Related Links:

Publication date: Available online 26 May 2018Source: Journal de Mycologie MédicaleAuthor(s): A. Sharifpour, N. Gholinejad-Ghadi, R. Ghasemian, Z. Seifi, S.R. Aghili, E. Zaboli, R. Abdi, T. ShokohiAbstractThe patients with hematologic malignancies and hematopoietic stem cell transplantation (HSCT) recipients are at high risk for invasive fungal diseases (IFDs) mainly due to the severe and prolonged neutropenia related to high-dose chemotherapy. Voriconazole prophylaxis is recommended for possible IFDs. Mucormycosis is a fulminant infection, which may occur after voriconazole prophylaxis for invasive aspergillosis in…

Publication date: June 2018Source: Best Practice &Research Clinical Haematology, Volume 31, Issue 2Author(s): Sophia Danhof, Michael Hudecek, Eric L. SmithAbstractHarnessing the endogenous immune system to eliminate malignant cells has long been an intriguing approach. After considerable success in the treatment of B-cell acute lymphoblastic leukemia, chimeric antigen receptor (CAR)-modified T cells have entered early clinical evaluation in the field of multiple myeloma (MM). The choice of suitable non-CD19 target antigens is challenging and a variety of myeloma-associated surface molecules have been under preclinical …

Publication date: 2017Source: Leukemia Research Reports, Volume 8Author(s): Chana L. GlasserAbstractTumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelog…

ConclusionAntibacterial prophylaxis mainly with coverage against Gram-positive bacteria is recommended in pediatric patients with AML. For ALL patients, prophylaxis may be considered for patients who are undergoing intensive chemotherapy phases and are at high risk for infections with ciprofloxacin being the most commonly used agent. In general more studies are needed to determine the role of antibacterial prophylaxis in pediatric patients with leukemia.

Publication date: March 2018Source: Hematology/Oncology and Stem Cell Therapy, Volume 11, Issue 1Author(s): Tahani Hani Sarrawi, Ismael Zayyat, Fareed Barakat, Maha Rezeq, Salam Abu Jmaian, Faris MadanatAbstractMinimal residual disease (MRD) monitoring opened a new era for childhood acute lymphoblastic leukemia (ALL), and is widely used for risk adapted therapy in the major study groups (Borowitz et al. 2015; Eckert et al., 2015; Peregud-Pogorzelsk et al., 2003). MRD is measured either by polymerase chain reaction (PCR) or flow cytometry (FCM) (Campana, 2009). Most studies have concentrated on measuring MRD during or at en…

Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Nicholas J. Short, Hagop Kantarjian, Ching-Hon Pui, Anthony Goldstone, Elias JabbourAbstractThe widespread adoption of Bcr–Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph+ ALL was historically associated with cure rates of 

ConclusionIntensified chemotherapy protocols for adult ALL have succeeded in achieving better survival rates in adults, especially younger adults. The low overall survival found with GMALL in Brazil’s public hospital denotes the importance of optimizing the adaptations of international protocols for treatment of ALL in nondeveloped countries and, in parallel, improving supportive care in public services.

In conclusion, these findings have identified a molecular mechanism underlying LMO2/ZEB1-mediated leukaemogenesis, paving a way for treating T-ALL with a new strategy of epigenetic inhibitors.

Induction chemotherapy results in high remission rate in high risk (HR) and very high risk (VHR) childhood acute lymphoblastic leukemia (ALL), but is associated with significant morbidity [1,2]. HR B-ALL is defined as: white blood cell count (WBC) ≥50,000/µL or age ≥10 years (National Cancer Institute (NCI) criteria) at presentation, or/and central nervous system (CNS) positive leukemia, or testicular leukemia [3–5]. Patients who are>13 years or experience induction failures; and/or if the leukemia blasts harbor mixed-lineage leukemia gene (MLL) rearrangements or intrachromosomal amplification of chrom…

Source: Leukemia ResearchCategory: Hematology Authors: Tags: Research paper Source Type: research

In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome–negative (Ph–) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 postbaseline result were…

Source: BloodCategory: Hematology Authors: Tags: Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research

Source link


Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image